Covidien Ltd. (NYSE:COV)

CAPS Rating: 5 out of 5

The Company is in the business of developing, manufacturing and distributing medical devices and supplies, diagnostic imaging agents, pharmaceuticals and other healthcare products for use in clinical and home settings.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 8/1/2014 12:36:48 PM : Outperform Start Price: $69.90 COV Score: +37.57

Div. (Yield) $1.28 (1.5%)

Recs

0
Member Avatar smmart2 (< 20) Submitted: 11/14/2013 5:10:17 PM : Outperform Start Price: $64.98 COV Score: +43.68

Recent spin-off allows the company to focus on core growthing business.
Strong cash flow and clear strategy on return of capital to shareholders.

Recs

0
Member Avatar CMCassociates (68.86) Submitted: 11/7/2013 8:10:16 PM : Outperform Start Price: $60.99 COV Score: +50.99

From the value investor's perspective, Covidien stands out as a reliably impressive performer considering its ROE, ROA, 5 year trailing earnings growth, and quick ratio. COV's ROE is consistently quite attractive.

Recs

0
Member Avatar BrentonKJ (26.76) Submitted: 10/13/2012 2:28:14 PM : Outperform Start Price: $53.04 COV Score: +47.77

Great management. Good PE and solid dividend. Investing heavily in R and D.

Recs

0
Member Avatar tomd728 (30.54) Submitted: 10/4/2012 9:50:53 AM : Outperform Start Price: $57.54 COV Score: +37.37

In the forefront of developing,acquiring,marketing and execution....

What else you want ? The COV team is doing all the
right moves to bring COV higher with respectable P:E:,P:S,Cash Flow (after cap ex).

Recs

0
Member Avatar evanjfried (< 20) Submitted: 7/26/2012 11:19:09 PM : Outperform Start Price: $51.70 COV Score: +48.59

The public needs training in their ability to evaluate stocks as per experience.

Recs

0
Member Avatar MrMilken (< 20) Submitted: 7/9/2012 12:32:32 PM : Outperform Start Price: $50.98 COV Score: +48.60

Good management, favorable environment.

Recs

0
Member Avatar jermskirk (86.90) Submitted: 5/25/2012 1:11:14 PM : Outperform Start Price: $51.33 COV Score: +44.87

More growth, higher margins post spin-off of pharma

Recs

1
Member Avatar ceejayoh (63.59) Submitted: 12/30/2011 7:15:32 AM : Outperform Start Price: $42.67 COV Score: +79.06

Picked on the recommendation of TMFdeej

Recs

0
Member Avatar FrancineT (< 20) Submitted: 5/23/2011 1:19:56 PM : Outperform Start Price: $52.29 COV Score: +40.61

Mechanical formula YLDEARNYEAR2

Recs

0
Member Avatar stovkey1highdiv (35.70) Submitted: 5/12/2011 9:58:29 AM : Outperform Start Price: $52.13 COV Score: +43.22

key03, 1.4% annual dividend

Recs

0
Member Avatar Superannuation (54.31) Submitted: 12/30/2010 11:52:36 PM : Outperform Start Price: $42.50 COV Score: +78.12

50 crossing 200 strong fundamentals

Recs

0
Member Avatar DeadmanLiving (70.06) Submitted: 12/9/2010 3:02:11 PM : Outperform Start Price: $40.46 COV Score: +88.32

Raymond James Picks 2011

Recs

0
Member Avatar bobabushka (73.25) Submitted: 10/27/2010 10:45:32 AM : Outperform Start Price: $37.61 COV Score: +98.58

Growth in 5 to 10 years. Probably longer. Medical devices medical devices medical devices... we'll all be needing them and they're leading the niche markets, sopping up whatever they can that looks valuable.

Recs

0
Member Avatar MizzouFanVan (90.25) Submitted: 10/25/2010 2:05:48 PM : Outperform Start Price: $37.58 COV Score: +100.99

Stock Picker - 5 Star, Pays Dividend, Down at Least 20% over last 12 months

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 10/4/2010 3:23:03 PM : Outperform Start Price: $37.22 COV Score: +95.46

Has the look of value

Recs

0
Member Avatar clm5567 (72.51) Submitted: 9/15/2010 8:03:13 PM : Outperform Start Price: $36.50 COV Score: +99.40

This is a very strong company with very little debt. They are also leaders in the areas they serve.

Recs

0
Member Avatar SugarAddict5 (63.94) Submitted: 9/14/2010 7:10:05 PM : Outperform Start Price: $34.85 COV Score: +112.08

Undervalued, good financials.

Recs

4
Member Avatar Drew2142 (98.88) Submitted: 6/17/2010 2:27:03 PM : Outperform Start Price: $37.58 COV Score: +83.87

Tyco who? Since the spin off, in the the last 3 years these guys have made acquisition after acquisition. This includes the 2+ billion for Ev3 June 9th, and oh yeah, the 250+ Million for Somanetics a few days ago...June 16th. The commitment to grow, and willingness to do that through acqusitions (and organically when possible), and then actually go out and make some fairly smart purchases (reasonably priced though... not home runs by any stretch) means profits for the company. Profits for the company, means profits for the investors. They seem to be a market-leader in almost all of their divisions, and if they aren't, they certainly aren't bashful in selling them off for hundreds of millions using that money to gobble up smaller niche leaders and plug gaps in the portfolio.

How about the innovator of the year award in 2009? That's probably a pretty good sign of what direction these guys intend to head. The commitment to innvovate, grow, shed losing brands/divisions, and push it's titantic-sized employee force means that the leaders at the top have their eyes on target, and that target keeps moving forward. I'm all for a company that has a ton of net cash coming in, and wants to put it use instead of just watching the bank account grow. Especially if they do it wisely, which COV appears to be doing.

The whole sector has taken a punch in the gut lately. COV isn't the best deal out there value-wise right now (BDX, BCR, and a few other look more attractive). But actions sometime speak louder than anything else, and i certainly like what i see for a long-term investment.

Recs

0
Member Avatar iksnamyzs (74.55) Submitted: 10/13/2009 8:42:56 PM : Outperform Start Price: $39.71 COV Score: +69.75

good company in healthcare sector

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement